|
Prescription Drug Search
Strengths available for Filgrastim prefilled syringe:
Strengths available for Filgrastim vial:
Browse Alphabetically:
A
·
B
·
C
·
D
·
E
·
F
·
G
·
H
·
I
·
J
·
K
·
L
·
M
·
N
O
·
P
·
Q
·
R
·
S
·
T
·
U
·
V
·
W
·
X
·
Y
·
Z
·
#
Information about MyGlobalPharmacy.com
List of countries where we can ship Filgrastim:
- Albania
- Algeria
- Antigua and Barbuda
- Armenia
- Bangladesh
- Belarus
- Belize
- Brazil
- Bulgaria
- Costa Rica
- Cyprus
- Czech Republic
- Denmark
- Egypt
- Estonia
- Fiji
- France
- Guam
- Hungary
- India
- Iran
- Japan
- Korea, South
- Liechtenstein
- Mauritius
- New Zealand
- Poland
- Russian Federation
- Saint Lucia
- Seychelles
- Singapore
- Sweden
- Switzerland
- Thailand
- Tonga
- Trinidad and Tobago
- Turkey
- United Kingdom, UK
- United States, US
- Yemen
Latest news releases on Filgrastim:
Marrow registry recruits donors, raises awareness - NorthJersey.com
It's important to note that while O'Connor was asked to donate bone marrow, the majority of donors are asked for stem cells, which are extracted via a non-surgical procedure after the patient takes a drug called filgrastim for several days to increase the ...
Biocon-Mylan collaboration drug portfolio worth $33 bn - Business Standard
The two companies are planning to come out with biosimilars such as "Trastuzumab, Peg-filgrastim, Bevacizumab, Adalimumab and Eternacept", which could be used in treating various ailments including cancer and psoriasis. The collaboration combines "Biocon's ...
FDA’s Hearing for Biosimilars Showcased Issues Ranging From Definitions to Study Requirements to IP - Genetic Engineering News
Its products include anemia treatment Retacrit in the EU and biosimilar filgrastim product Nivestim, sold in the EU and Australia for stimulating production of white blood cells in patients receiving cytotoxic chemotherapy. Samant Ramachandra ...
RNCOS Releases a New Report - G-CSF Biosimilars Market Forecast to 2015 - SBWire
In 2010, the G-CSF biosimilars had a 33% share in the global biosimilars market. It is expected that the patent expiries of Neupogen (filgrastim) in 2013 and Neulasta (pegfilgrastim) in 2015 will make the way for the entry of G-CSF biosimilars ...
